stockrowAbCellera Biologics Inc.
ABCL Healthcare Biotechnology
AbCellera Biologics Inc.’s revenue for fiscal 2025 (year ended December 2025) was $75.1 million, up 160.6% from fiscal 2024.
- Revenue
- −76.3%
- EPS
- −50.0%
- Free cash flow
- +152.0%
Quarter to June 2026, against a year earlier
Follow ABCL
Alert me
AbCellera Biologics Inc. (ABCL) Net income
AbCellera Biologics Inc.'s net income for fiscal 2025 was −$146.4M, compared with −$162.9M in fiscal 2024. Over the twelve months to 30 June 2026 it was −$164.7M. Over the past ten years it has ranged from −$162.9M (fiscal 2024) to $158.5M (fiscal 2022); the current reading is higher than 22% of that period. AbCellera Biologics Inc. ranks 497th of 605 Biotechnology companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | −$146.4M | — |
| FY2024 | −$162.9M | — |
| FY2023 | −$146.4M | — |
| FY2022 | $158.5M | 3.29% |
| FY2021 | $153.5M | 29.05% |
| FY2020 | $118.9M | — |
| FY2019 | −$2.2M | — |
| FY2018 | $309.0K | — |
| FY2017 | $0.00 | — |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | −$55.4M | — |
| Mar 2026 | −$43.2M | — |
| Dec 2025 | −$8.9M | — |
| Sep 2025 | −$57.1M | — |
| 24 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $362.2M |
| ARQT Arcutis Biotherapeutics, Inc. compare | $29.9M |
| TNGX Tango Therapeutics, Inc. compare | −$123.7M |
| ABCL AbCellera Biologics Inc. | −$164.7M |
| PBLS Parabilis Medicines, Inc. compare | −$170.9M |
| EWTX Edgewise Therapeutics, Inc. compare | −$197.2M |
| IOVA Iovance Biotherapeutics, Inc. compare | −$220.5M |
| RLAY Relay Therapeutics, Inc. compare | −$286.0M |
| XENE Xenon Pharmaceuticals Inc. compare | −$409.2M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on ABCL
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement